Sobi KOL investor event: the journey for Vonjo®
19 July 2023 15:30 CEST, 14:30 BST, 09:30 EDTFollowing the completion of Sobi’s acquisition of CTI Biopharma, Sobi’s management will host a virtual KOL event. Sarah Buckley, VP and Head of Clinical Affairs at CTI Biopharma, and Key Opinion Leader, Dr John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, will discuss the clinical and commercial opportunity of CTI Biopharma’s lead asset, Vonjo (pacritinib). The presentation can be followed live here or afterwards on